CAARE: Characterization and Recovery of Bionanoparticles for Vaccine Delivery and Gene Therapy
The Doctoral Network CAARE - Characterization and Recovery of Bionanoparticles for Vaccine Delivery and Gene Therapy focuses on a rapidly em...
2024-06-25 - 2028-09-30 | Financiado
2024-06-25 - 2028-09-30 | Financiado
UltiMalVax: A Vaccine Targeting Eradication of Malaria
GENIBET BIOPHARMACEUTICALS SA
participó en un
HORIZON EUROPE:
HORIZON-HLTH-2022-DISEASE-06-two-stage
Malaria killed about 640 thousand people in 2020, largely young children in Africa. Rapid recent progress has led to two anti-sporozoite vac...
2023-04-21 - 2027-04-30 | Financiado
2023-04-21 - 2027-04-30 | Financiado
TRANSVAC-DS: DESIGN STUDY FOR A EUROPEAN VACCINE INFRASTRUCTURE
GENIBET BIOPHARMACEUTICALS SA
participó en un
H2020:
H2020-SC5-2018-2019-2020
The TRANSVAC-DS project further builds on the outstanding success of EC-funded projects:TRANSVAC1 and TRANSVAC2 and proposes the establishme...
2020-06-09 - 2023-02-28 | Financiado
2020-06-09 - 2023-02-28 | Financiado
CRUZIVAX: Vaccine for prevention and treatment of Trypanosoma cruzi infection
GENIBET BIOPHARMACEUTICALS SA
participó en un
H2020:
H2020-SC1-BHC-2018-2020
Chagas is a neglected disease endemic in 21 Latin-American countries caused by Trypanosoma cruzi. It is the largest parasitic disease burden...
2019-04-30 - 2025-02-28 | Financiado
2019-04-30 - 2025-02-28 | Financiado
TRANSVAC2: European Vaccine Research and Development Infrastructure
GENIBET BIOPHARMACEUTICALS SA
participó en un
H2020:
H2020-INFRAIA-2016-2017
TRANSVAC2 is the follow-up project to its successful predecessor project TRANSVAC, the European Network of Vaccine Research and Development...
2017-07-28 - 2023-04-30 | Financiado
2017-07-28 - 2023-04-30 | Financiado
DiViNe: Sustainable downstream processing of vaccines through incorporation of nanobiotechnologies novel a...
GENIBET BIOPHARMACEUTICALS SA
participó en un
H2020:
H2020-BIOTEC-2014-2015
In the vaccine industry, downstream processing is of extreme importance. Prophylactic vaccines aim at protecting healthy people, so any cont...
2015-02-11 - 2020-02-29 | Financiado
2015-02-11 - 2020-02-29 | Financiado
BRAINVECTORS: From Brain Gene Transfer Towards Gene Therapy Pharmacological Assessment of AAV CAV and LVV
GENIBET BIOPHARMACEUTICALS SA
participó en un
FP7:
"BRAINVECTORS aims devising new gene therapy(GT)-based treatments for Parkinson’s and other neurodegenerative diseases, in substitution of c...
Financiado
Financiado
SADEL: Scaffolds for alternative delivery
GENIBET BIOPHARMACEUTICALS SA
participó en un
FP7:
The SME-based SADEL consortium intends to develop the first generation of oral bio-therapeutics tackling disease targets in the digestive tr...
Financiado
Financiado
HepaMAb: Human monoclonal antibody therapy to prevent hepatitis C virus reinfection of liver transplants adv...
GENIBET BIOPHARMACEUTICALS SA
participó en un
FP7:
Worldwide, 200 million people are infected with the hepatitis C virus (HCV). An estimated 15 million individuals are living with HCV infecti...
Financiado
Financiado
BRAINCAV: NONHUMAN ADENOVIRUS VECTORS FOR GENE TRANSFER TO THE BRAIN
GENIBET BIOPHARMACEUTICALS SA
participó en un
FP7:
Formidable challenges remain to prevent and treat successfully neurodegenerative diseases. Traditional pharmacological approaches, as well a...
Financiado
Financiado
* No se disponen de datos de la empresa actual.